flecainide has been researched along with ALS - Amyotrophic Lateral Sclerosis in 1 studies
Flecainide: A potent anti-arrhythmia agent, effective in a wide range of ventricular and atrial ARRHYTHMIAS and TACHYCARDIAS.
flecainide : A monocarboxylic acid amide obtained by formal condensation of the carboxy group of 2,5-bis(2,2,2-trifluoroethoxy)benzoic acid with the primary amino group of piperidin-2-ylmethylamine. An antiarrhythmic agent used (in the form of its acetate salt) to prevent and treat tachyarrhythmia (abnormal fast rhythm of the heart).
| Excerpt | Relevance | Reference |
|---|---|---|
| "Flecainide-treated patients maintained stabilized peripheral axonal excitability over the study compared to placebo." | 6.80 | Flecainide in Amyotrophic Lateral Sclerosis as a Neuroprotective Strategy (FANS): A Randomized Placebo-Controlled Trial. ( Cheah, BC; Kiernan, MC; Kirby, A; Lin, CS; Mann, KP; Park, SB; Vucic, S; Winhammar, J; Zoing, MC, 2015) |
| "Flecainide-treated patients maintained stabilized peripheral axonal excitability over the study compared to placebo." | 2.80 | Flecainide in Amyotrophic Lateral Sclerosis as a Neuroprotective Strategy (FANS): A Randomized Placebo-Controlled Trial. ( Cheah, BC; Kiernan, MC; Kirby, A; Lin, CS; Mann, KP; Park, SB; Vucic, S; Winhammar, J; Zoing, MC, 2015) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 1 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Park, SB | 1 |
| Vucic, S | 1 |
| Cheah, BC | 1 |
| Lin, CS | 1 |
| Kirby, A | 1 |
| Mann, KP | 1 |
| Zoing, MC | 1 |
| Winhammar, J | 1 |
| Kiernan, MC | 1 |
1 trial available for flecainide and ALS - Amyotrophic Lateral Sclerosis
| Article | Year |
|---|---|
Flecainide in Amyotrophic Lateral Sclerosis as a Neuroprotective Strategy (FANS): A Randomized Placebo-Controlled Trial.
Topics: Adult; Amyotrophic Lateral Sclerosis; Female; Flecainide; Humans; Male; Middle Aged; Neuroprotective | 2015 |